Alpha-2 Agonist — Rosacea Erythema Pregnancy: There are no or limited data from use in pregnant women; as a precautionary measure it is preferable to avoid use during pregnancy. It is unknown whether brimonidine or its metabolites are excreted in human milk and a risk to the newborn/infant cannot be excluded - should not be used during breast-feeding.

Brimonidine Gel (Topical)

Brand names: Mirvaso

Brimonidine topical gel is an alpha-2 adrenergic agonist applied to the face to reduce the persistent facial erythema (redness) of rosacea.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: One application per 24 hours - up to 1 g of gel in total weight, corresponding to approximately five pea-sized amounts, applied as a thin layer across the entire face

Route: Cutaneous use only (face only)

Frequency: Once every 24 hours, at any time suitable for the patient, for as long as facial erythema is present

Max: 1 g of gel in total weight per 24 hours (approximately five pea-sized amounts)

Source is the eMC SPC for Mirvaso 3 mg/g gel (brimonidine, cutaneous gel for facial erythema of rosacea). Treatment should be initiated with a smaller amount of gel than the maximum for at least one week; the amount can then be increased gradually based on tolerability and patient response. Apply smoothly and evenly as a thin layer across the entire face (forehead, chin, nose and both cheeks), avoiding the eyes, eyelids, lips, mouth and the membrane of the inner nose; wash hands immediately after application. Do not exceed five pea-sized amounts or once-daily application - the safety of higher daily doses or repeated daily application has not been assessed. Do not apply to irritated skin (including following laser therapy) or open wounds. Exacerbation of rosacea symptoms is very common; if worsening erythema occurs, discontinue. Before resuming after temporary discontinuation for aggravated erythema or flushing, perform a test application on a small area of the face for at least one day. May be used with other cutaneous products and cosmetics, but only after the applied gel has dried. Elderly: no dose adjustment is necessary; experience above 65 years is limited. Paediatric: contraindicated in children aged less than 2 years; should not be used in children or adolescents aged 2 to 18 years; safety and efficacy under 18 years have not been established.

Dose adjustments

Renal

Mirvaso has not been studied in patients with hepatic and renal impairment.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to brimonidine or to any of the excipients
Children aged less than 2 years
Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or moclobemide)
Patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline, mianserin or mirtazapine) antidepressants which affect noradrenergic transmission

Side effects

Erythema, pruritus, rosacea (symptom exacerbation) and skin burning sensation (common; aggravated erythema and flushing reported post-marketing)
Flushing and pallor at the application site (common)
Headache, paraesthesia, dizziness, eyelid oedema, nasal congestion, dry mouth (uncommon)
Acne, allergic contact dermatitis, contact dermatitis, dry skin, skin pain, papular rash, skin irritation, facial swelling, urticaria (uncommon)
Bradycardia, hypotension including orthostatic hypotension and angioedema (rare, post-marketing; some cases required hospitalisation, some following laser procedures)

Interactions

No interaction studies have been performed (section 4.5)
MAO inhibitors and tricyclic/tetracyclic antidepressants affecting noradrenergic transmission - contraindicated (section 4.3)
Other systemic alpha-adrenergic receptor agonists - concomitant use may potentiate the undesirable effects of this class, particularly in patients with severe, unstable or uncontrolled cardiovascular disease, or with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma or Sjogren's syndrome

Clinical monograph

How it works

By stimulating alpha-2 adrenoceptors on cutaneous blood vessels it produces vasoconstriction of the dilated dermal vessels responsible for rosacea-associated redness.

Prescribing in practice

Some patients experience rebound or worsening erythema and flushing as the effect wears off, so a small test area and gradual introduction are advisable before regular facial use.
It treats redness only and has no effect on the inflammatory papules and pustules of rosacea, which need separate therapy.
Apply to intact skin only, avoiding the eyes, mouth and broken or irritated skin.

Monitoring

Review tolerability after initial use, watching specifically for rebound erythema, paradoxical flushing or contact irritation.

Counselling the patient

Apply a thin layer smoothly across the face once daily and wash your hands afterwards.
Be aware redness may sometimes return or worsen as the gel wears off; stop and seek advice if this is troublesome.

Evidence & guidelines

Efficacy for rosacea erythema is established in randomised controlled trials and reflected in the SPC.

Reference: Fowler et al. (2012) J Drugs Dermatol Brimonidine rosacea; BAD Rosacea Guidelines 2017; NICE CKS Rosacea; SPC Mirvaso; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Pathways